0819 ET - Sage Therapeutics is unlikely to accept Biogen's $7.22-a-share buyout bid, say analysts at Mizuho, who note the proposal implies a negative enterprise value for the biopharmaceutical company. In a research note, Mizuho's Uy Ear and Leo Watson say Biogen's bid came as a surprise to Sage's management, which believes the company is worth significantly more. Mizuho says Sage thinks Zurzuvae has "blockbuster plus" potential in postpartum depression and that there is significant value in its pipeline, including SAGE-319, which it is testing in various neurodevelopmental disorders. Sage up 1.3% to $7.60 premarket, above Biogen's takeout bid. Sage surged 35% on Monday. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
January 14, 2025 08:19 ET (13:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.